AbbVie has launched its Produodopa therapy for Parkinson’s disease onto the market in the EU, becoming the first and only 24-hour levodopa-based subcutaneous ...

AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator turned it down with a request for more data. Now, Vyalev (foscarbidopa and ...

Andrea Capelli also censured by fitness-to-practise committee for making student nurse ‘uncomfortable’ over Facebook messages ...

If you have advanced Parkinson’s disease (PD), you may hear about a treatment option called vyalev (foscarbidopa/foslevodopa). It was approved by the FDA in 2024 ...

Market forecasters project the CAR-T cell therapy market will surge from $3.87 billion in 2024 to $13.25 billion by 2030, driven by unprecedented efficacy in relapsed and refractory patient ...

Caribou plans a pivotal Phase 3 randomized trial evaluating approximately 250 patients in second-line large B-cell lymphoma. The FDA granted vispa-cel Regenerative Medicine Advanced Therapy, Orphan ...

Equity Insider News Commentary ? The oncology sector's pivot toward platform-based precision therapies has signaled smart money abandoning single-asset risk for companies engineering multiple drugs ...

The approval of subcutaneous amivantamab allows physicians flexibility in offering treatment for non–small cell lung cancer.

Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio ...

Martin Dietrich, MD, PhD, a medical oncologist at the Cancer Care Centers of Brevard and an assistant professor at the ...

The subcutaneous formulation of the bispecific antibody reduces treatment time to 1 minute vs 2-4 hours with IV infusion.